|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:cephalosporin
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:ATCCode
|
J01DB05
|
|
gptkbp:bioavailability
|
95%
|
|
gptkbp:CASNumber
|
92665-29-7
|
|
gptkbp:chemicalFormula
|
C18H19N3O5S
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:discoveredBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
gptkb:second-generation_cephalosporin
|
|
gptkbp:eliminationHalfLife
|
1.3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:indication
|
gptkb:sinusitis
gptkb:otitis_media
skin infections
tonsillitis
urinary tract infections
pharyngitis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
389.43 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
36%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
allergic reaction
rash
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:Cefzil
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cefprozil
|